At today’s CX Renal Denervation Session Great Debate, delegates voted 3:1 against the motion that renal denervation should be used routinely to treat hypertension. As all of the speakers, regardless of which side of the debate they were, agreed that renal denervation should only be used to treat patients with resistant hypertension, the real focus of the debate centred on what was meant by the word “routine”.
Mel Lobo (London, UK), who was supporting the motion that renal denervation should be part of routine clinical practice to treat hypertension, claimed that the definition of routine was a “key issue” in the debate. He explained that patients who were suitable candidates for the intervention belonged to a highly selective group of patients, who had true resistant hypertension (ie. non-concordance with medication and other causes of resistant hypertension had been ruled out) and who would be managed by hypertension specialists rather than by primary care physicians. Lobo added that, in his view, renal denervation should become “step five” of the UK National Institute for Health and Clinical Excellence (NICE) pathway for the management of hypertension, commenting: “We do not have any randomised controlled trial data for step four